Crossject
Develops emergency medications delivered via a needle-free auto-injector platform.
ALCJ | PA
Overview
Corporate Details
- ISIN(s):
- FR0004178614 (+6 more)
- LEI:
- 969500W1VTFNL2D85A65
- Country:
- France
- Address:
- 6 Rue Pauline Kergomard, 21000 dijon
- Website:
- https://www.crossject.com/en
- Sector:
- Manufacturing
Description
Crossject is a specialty pharmaceutical company focused on developing and commercializing medications for life-threatening emergency situations. The company's core technology is ZENEO®, a proprietary, pre-filled, single-use needle-free auto-injector. This platform is designed to enable patients or untrained caregivers to rapidly, safely, and reliably administer emergency treatments. Crossject's product pipeline targets critical conditions such as epileptic seizures, acute adrenal crisis, and severe allergic reactions (anaphylaxis), aiming to improve patient outcomes by simplifying drug delivery in urgent scenarios.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-08-22 07:30 |
Crossject to Present at the H.C. Wainwright 26th Annual Global Investment Confe…
|
English | 195.3 KB | ||
| 2024-08-19 17:30 |
Crossject appoints Tony Tipton as U.S. Chief Operating Officer in Preparation f…
|
English | 191.8 KB | ||
| 2024-08-19 17:30 |
Tony Tipton nommé au poste de directeur des opérations États-Unis de Crossject …
|
French | 197.5 KB | ||
| 2024-07-18 07:30 |
Crossject franchit une nouvelle étape clé dans la fabrication de ZEPIZURE®
|
French | 238.9 KB | ||
| 2024-07-18 07:30 |
Crossject achieves key ZEPIZURE® manufacturing milestone
|
English | 222.9 KB | ||
| 2024-07-10 07:30 |
Crossject obtient 6,9 millions d'euros de financement public dans le cadre du p…
|
French | 273.4 KB | ||
| 2024-07-10 07:30 |
Crossject is awarded a 6.9 million euros financing from the French Government, …
|
English | 306.3 KB | ||
| 2024-07-05 10:09 |
Crossject : Information relative au nombre total de droits de vote et d'actions…
|
French | 188.3 KB | ||
| 2024-06-26 07:30 |
Crossject met en perspective le potentiel de ZEPIZURE® à la lumière de l'étude …
|
French | 289.0 KB | ||
| 2024-06-26 07:30 |
Crossject elaborates on ZEPIZURE® potential in light of landmark RAMPART study …
|
English | 265.8 KB | ||
| 2024-06-18 12:30 |
Crossject : Information relative au nombre total de droits de vote et d'actions…
|
French | 175.0 KB | ||
| 2024-06-13 09:36 |
Crossject : Information relative au nombre total de droits de vote et d'actions…
|
French | 174.5 KB | ||
| 2024-06-12 07:30 |
Crossject appoints Dan Chiche, MD as Chief Medical Officer North America
|
English | 229.7 KB | ||
| 2024-06-12 07:30 |
Crossject nomme Dan Chiche, MD au poste de Directeur Médical Amérique du Nord
|
French | 233.4 KB | ||
| 2024-06-04 19:30 |
Crossject annonce le vif succès de son augmentation de capital de 8 millions d’…
|
French | 227.6 KB |
Automate Your Workflow. Get a real-time feed of all Crossject filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Crossject
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Crossject via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-06-24 | N/A | Other | Buy | 20,000 | N/A |
| 2024-06-14 | N/A | Other | Other | 10,979 | 20,289.19 EUR |
| 2024-06-06 | N/A | Other | Other | 1,058,617 | 1,956,324.22 EUR |
| 2024-06-06 | N/A | Other | Other | 16,106 | 29,763.89 EUR |
| 2024-06-06 | N/A | Other | Other | 10,275 | 18,988.20 EUR |
| 2024-06-06 | N/A | Other | Other | 10,074 | 18,616.75 EUR |
| 2024-06-06 | N/A | Other | Buy | 5,536 | 10,230.53 EUR |
| 2023-03-06 | N/A | Other | Other | 22,859 | 75,434.70 EUR |
Peer Companies
